Patient characteristic | OS | BCSS | |||||
---|---|---|---|---|---|---|---|
Hazard Ratio | CI (95%) | P | Hazard Ratio | CI (95%) | P | ||
Age at diagnosis | 20–30 | Ref |  |  | Ref |  |  |
 | 31–40 | 0.876 | 0.672–1.141 | 0.326 | 0.982 | 0.736–1.309 | 0.899 |
 | 41–50 | 0.699 | 0.542–0.903 | 0.006 | 0.748 | 0.566–0.989 | 0.041 |
 | 51–60 | 0.946 | 0.735–1.217 | 0.665 | 0.920 | 0.698–1.212 | 0.553 |
 | 61–70 | 1.343 | 1.045–1.726 | 0.021 | 0.942 | 0.714–1.243 | 0.674 |
 | 71–80 | 3.008 | 2.341–3.865 |  < 0.001 | 1.498 | 1.133–1.979 | 0.004 |
Race | White | Ref | Â | Â | Ref | Â | Â |
 | Black | 1.600 | 1.505–1.701 |  < 0.001 | 1.544 | 1.423–1.674 |  < 0.001 |
 | Others | 0.843 | 0.787–0.903 |  < 0.001 | 0.889 | 0.809–1.976 | 0.014 |
Histological grade | 1 | Ref | Â | Â | Ref | Â | Â |
 | 2 | 1.172 | 1.102–1.246 |  < 0.001 | 1.630 | 1.451–1.832 |  < 0.001 |
 | 3 | 1.540 | 1.439–1.648 |  < 0.001 | 2.682 | 2.377–3.025 |  < 0.001 |
T stage | 1 | Ref | Â | Â | Ref | Â | Â |
 | 2 | 1.606 | 1.476–1.747 |  < 0.001 | 1.697 | 1.521–1.894 |  < 0.001 |
 | 3 | 2.155 | 1.929–2.407 |  < 0.001 | 2.559 | 2.229–2.938 |  < 0.001 |
 | 4 | 3.614 | 3.159–4.135 |  < 0.001 | 4.497 | 3.831–5.279 |  < 0.001 |
N stage | 0 | Ref | Â | Â | Ref | Â | Â |
 | 1 | 1.413 | 1.319–1.514 |  < 0.001 | 1.679 | 1.534–1.838 |  < 0.001 |
 | 2 | 1.974 | 1.730–2.252 |  < 0.001 | 2.550 | 2.179–2.984 |  < 0.001 |
 | 3 | 2.867 | 2.514–3.369 |  < 0.001 | 3.870 | 3.315–4.517 |  < 0.001 |
HER-2 | Negative | - | Â | Â | Ref | Â | Â |
 | Positive | - | - | - | 0.599 | 0.553–0.650 |  < 0.001 |
Stage | I | Ref | Â | Â | Ref | Â | Â |
 | II | 1.005 | 0.910–1.109 | 0.925 | 1.574 | 1.368–1.811 |  < 0.001 |
 | III | 1.163 | 0.987–1.370 | 0.072 | 1.928 | 1.564–2.377 |  < 0.001 |
HR status | ER + /PR +  | Ref |  |  | Ref |  |  |
 | ER + /PR- | 1.247 | 1.173–1.325 |  < 0.001 | 1.686 | 1.550–1.834 |  < 0.001 |
 | ER-/PR +  | 1.567 | 1.321–1.858 |  < 0.001 | 2.090 | 1.696–2.574 |  < 0.001 |
 | ER-/PR- | 1.501 | 1.417–1.589 |  < 0.001 | 2.019 | 1.872–2.178 |  < 0.001 |